再生醫療雙法難產對於台灣生技公司股價之影響

TMUIR > College of Management > Biotechnology Executive Master's Degree in Business Administration (EMBA) > Dissertations/Theses > Item 987654321/64561

Please use this identifier to cite or link to this item: http://libir.tmu.edu.tw/handle/987654321/64561

Title:	再生醫療雙法難產對於台灣生技公司股價之影響 The Impact of the Stalled Dual Laws on Regenerative Medicine on the Stock Prices of Taiwanese Biotech Companies
Authors:	施旻瑩 Shih, Ming-Ying
Contributors:	管理學院生物科技高階管理碩士在職專班蕭育仁
Keywords:	再生醫療雙法;生技產業;股價影響;政策變動 Regenerative Medicine;Biotechnology industry;Stock Price Impact;Policy Changes
Date:	2024-01-05
Issue Date:	2024-11-06 10:42:01 (UTC+8)
Abstract:	本論文深入探討再生醫療雙法對台灣生技產業股價的影響，透過對法案提出、審議和二讀未果等關鍵事件的深入分析，揭示了市場在不同階段的細緻反應。第一章中，介紹再生醫療雙法的制定背景，強調政策的重要性。第二章進行詳盡的文獻回顧，聚焦全球相關法規的影響，提供了本研究的理論依據。第三章闡述研究方法，強調事件研究法的優勢和資料收集的細節。在第四章中，本研究呈現了具體的實證結果，發現市場對再生醫療雙法的反應呈現出時間演變的特點，並進一步挖掘了市場受到影響的具體原因。最後，第五章的結論與建議提供了深刻的洞察，強調生技公司應即時因應政策變動，建立風險管理策略，並與政府積極互動，以促進產業的健康發展。 This thesis delves into the nuanced impact of the Regenerative Medicine Act on the stock prices of Taiwan's biotechnology industry. Through an in-depth analysis of key events such as the proposal, review, and unsuccessful second reading of the bill, it unveils the market's intricate responses at different stages. In Chapter 1, the introduction emphasizes the significance of policy by outlining the background of the Regenerative Medicine Act. Chapter 2 conducts a comprehensive literature review, focusing on the global impact of relevant regulations, providing a robust theoretical foundation for this study. Chapter 3 elucidates the research methods, emphasizing the advantages of the event study approach and detailing data collection. In Chapter 4, this research presents concrete empirical results, discovering the evolving nature of the market's response to the Regenerative Medicine Act and further exploring the specific reasons behind market influence. Finally, Chapter 5's conclusion and recommendations provide profound insights, emphasizing that biotech companies should respond promptly to policy changes, establish risk management strategies, and actively engage with the government to foster industry development.
Description:	碩士指導教授：蕭育仁口試委員：蕭育仁口試委員：周冠男口試委員：張巧真
Note:	論文公開日期：2024-01-17
Data Type:	thesis
Appears in Collections:	[Biotechnology Executive Master's Degree in Business Administration (EMBA)] Dissertations/Theses

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	74	View/Open

Loading...